• 1
    Poynard T, Bedossa P, Chevallier M, et al.A comparison of three interferon alpha-2b regimes for long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457 62.
  • 2
    Boucher E, Jouanolle H, André P, et al.Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology 1995; 21: 322 7.
  • 3
    Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Faruki H. A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. J Viral Hepat 1997; 4: 101 6.
  • 4
    Beloqui O, Prieto J, Suarez M, et al.N-acetylcysteine enhances the response to interferon-alpha in chronic hepatitis C. A pilot study. J Interferon Res 1993; 13: 279 82.
  • 5
    Reichard O, Norkrans G, Frydé NA, et al.Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83 7.
  • 6
    Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 1681 7.
  • 7
    Okano T, Ari K, Shindo M. Efficacy of interferon combined glycyrrhizin in patients with chronic hepatitis C resistant to interferon therapy. Nippon Rinsho 1994; 52: 1823 7.
  • 8
    Sherman KE, Sjogren M, Creager RL, et al.Combination therapy with thymosin and interferon for the treatment of chronic hepatitis C infection: a randomised, placebo-controlled double-blind trial. Hepatology 1998; 27: 1128 35.
  • 9
    Negro F, Male PJ, Perrin L, Giostra E, Hadengue A. Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone. J Hepatol 1998; 29: 369 74.
  • 10
    Caldwell SH, Dickson RC, Driscoll C, Sue M, Yeaton P. A pilot study using piroxicam with interferon α 2b in the retreatment of refractory hepatitis C [abstract]. Gastroenterology 1995; 108: 1043A1043A.
  • 11
    Hannigan GE & Williams BRG. Signal transduction by interferon-alpha through arachidonic metabolism. Sci 1991; 251: 204 7.
  • 12
    Tsuboi I, Tanaka H, Nakao M, Shichijo S, Itoh K. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down regulation of IL-6 production. Cytokine 1995; 7: 372 9.
  • 13
    Baskin G. Interferon-signalling through arachidonic acid-dependent pathways: a clue to adjuvant therapy for chronic hepatitis? Hepatology 1991; 14: 392 4.
  • 14
    Andreone P, Cursaro C, Gasbarrini G. Interferon-alpha increases prostaglandin E2 production by cultured liver biopsy in patients with chronic viral hepatitis: can non-steroidal anti-inflammatory drugs improve the therapeutic response to interferon? J Hepatol 1993; 19: 228 31.
  • 15
    Andreone P, Cursaro C, Gramenzi A, et al.Indomethacin enhaces serum 2′5′-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis infection. J Hepatol 1994; 21: 984 8.
  • 16
    Giambartolomei S, Artini M, Almerighi C, Levrero M, Balsano C. Modulation of IFN-alpha signalling by NSAIDs: therapeutical implication in HCV patients [abstract]. J Hepatol 1998; 28(Suppl. 1): 103103.
  • 17
    Zarski JP, Maynard-Muet M, Chousterman S, et al.Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon. Hepatology 1998; 27: 862 7.
  • 18
    Knodell RG, Ishak K, Black W, et al.Formulation and application of a numerical scoring system for assessing histological activity in asymtomatic chronic active hepatitis. Hepatology 1981; 1: 431 5.
  • 19
    Imberti L, Cariani E, Bettinardi A, Zonaro A, Albertini A, Primi D. An immunoassay for specific amplified HCV sequences. J Virol Meth 1991; 34: 233 43.
  • 20
    Viasoz S, Zilbert A, Ramakrishnan K, et al.Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Meth 1994; 48: 81 92.
  • 21
    Detmer J, Lagier R, Flyn R, et al.Accurate quantification of hepatitis C virus RNA (HCV-RNA) from all HCV genotypes by using branched DNA technology. J Clin Microbiol 1996; 34: 901 7.
  • 22
    Bellobuono A, Mondazzi L, Tempini S, et al.Should patients with early loss of serum HCV RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months? J Hepatol 1999; 30: 8 13.
  • 23
    Andreone P, Gramenzi A, Cursaro C, et al.A randomised controlled trial of IFN α + ketoprofen or IFN α + Ribavirin in HCV chronic active hepatitis (CAH) non responder to IFN α alone [abstract]. Hepatology 1995; 22: 119A119A.
  • 24
    Muñoz A, Levi D, Podestà A, et al.Evaluation of different doses of ketoprofen associated to interferon in the treatment of chronic hepatitis C. A prospective and randomized study [abstract]. Hepatology 1998; 28: 712A712A.
  • 25
    Anderson FH, Zeng L, Yoshida EM, Rock NR. Failure of ketoprofen and interferon combination therapy to improve interferon-resistant chronic hepatitis C. Can J Gastroenterol 1997; 11: 294 7.
  • 26
    Nunes FA, Santoro J, Kaufman B, et al.Interferon-alpha and ribavirin alone or in combination with ketoprofen for the treatment of patients with chronic hepatitis C who have not responded to previous interferon therapy [abstract]. Hepatology 1998; 28: 579A579A.
  • 27
    Di Costanzo GG, Ascione A, Lanza AG, Utech W, Capibianco G, Vacco C. Adjuvant therapy for interferon-resistant patients: do cycloxygenase inhibitors have any role? A pilot study. J Hepatol 1995; 23: 359 60.
  • 28
    Giannelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O. 2′,5′-oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993; 13: 57 60.
  • 29
    Pawlotsky JM, Hovanessian A, Roudot-Thoraval F, et al.Activity of the interferon-induced 2′,5′-oligoadenylate synthetase in patients with chronic hepatitis C. J Interfer Res 1995; 15: 857 62.
  • 30
    Andreone P, Cursaro C, Gramenzi A, et al.Modulation of Th1/Th2 cytokine profile and antiviral response by interferon a (IFNa) and non steroidal anti-inflammatory drugs (NSAIDs) in hepatitis C virus (HCV) [abstract]. Hepatology 1997; 26: 410A410A.
  • 31
    Davis GL & Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Suppl. 1): 122S 7S.
  • 32
    Marchetto S, Fabbri C, Mazzeo C, et al.Cocktail therapy for chronic hepatitis C preliminary results [abstract]. Hepatology 1998; 28: 211A211A.